patent.fyi
Applications  /  US 2026/0356835
United States Patent Application Publication

US 2026/0356835 A1

Published
Nov 12, 2026
Filed
May 22, 2024
Earliest date on the face
May 23, 2023
Classification
C07D 471/04
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Oxygen at the J1 position

What ifWhat if J1 is a ring oxygen bonded to its two neighboring atoms?
Claim language“J1 is CR3”

The oxygen forms two sigma bonds and contributes one lone pair to the aromatic π system. It preserves the ring connection at J1 and changes the local bond polarity.

1.2Sulfur at the J2 position

What ifWhat if J2 is a thiophene-type sulfur atom bonded to its two neighboring ring atoms?
Claim language“J2 is CR4”

The divalent sulfur forms two bonds in the five-membered ring and contributes a lone pair to aromatic conjugation. Its polarizable electron cloud changes the electronic environment near J2.

1.9Partially saturated fused core

What ifWhat if the bicyclic core consists of a benzene ring fused to a saturated nitrogen-containing ring?
Claim language“is a heteroaryl ring”

An indoline core uses a shared carbon–carbon edge to connect the aromatic benzene ring and a five-membered ring with two methylene groups. The fused core fixes the relative positions of the two rings, and the amine provides a site for protonation.

1.10Ether bridge to the terminal ring

What ifWhat if L1 is a single ether oxygen linking the bicyclic core to a cyclopropyl R1 group?
Claim language“an optionally substituted C1-6 alkylene”

An aryl cyclopropyl ether connects the core carbon and a cyclopropyl carbon through two carbon–oxygen bonds. The oxygen serves as a short connector and provides a hydrogen-bond acceptor.

1.11Single ring as a spacer

What ifWhat if L1 is a trans-cyclohexane-1,4-diyl spacer with one attachment at each end?
Claim language“an optionally substituted 7-12 membered bicyclic ring structure”

The six-membered ring connects the bicyclic core at C1 and R1 at C4. The trans configuration gives a chair conformer with both attachments in equatorial positions.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Fused heteroaryl ligand for copper capture

A sorbent uses 8-hydroxyquinoline as a fused bicyclic heteroaryl ligand and porous silica as the support. A propyl amide tether connects the silica surface to the ligand at carbon 5 and leaves the ring nitrogen and hydroxyl group available for coordination. Water flows through a packed bed, where dissolved copper binds to the immobilized ligand. Dilute acid protonates the donor groups and releases the copper for collection.

Component substitution

Oxetane in place of cyclobutane

An oxetan-3-yl group replaces a cyclobutyl group at R1 while L1 retains its original attachment to the fused core. L1 bonds to carbon 3 of the oxetane opposite the ring oxygen. This arrangement retains a four-membered terminal ring and introduces an ether oxygen that accepts hydrogen bonds.

Ether bridge at the R5 position

An ether oxygen replaces a methylene group in the L3 linkage between a carbon at J3 and a cyclopropyl G2 group. The resulting cyclopropoxy substituent bonds to the fused core through oxygen and to the terminal ring through a cyclopropane carbon. The oxygen retains a one-atom bridge and adds a hydrogen-bond acceptor between the two rings.

Parameter or scale variation

Three linker lengths for matched analogs

A matched series connects the same fused bicyclic core to a cyclopropyl R1 group through linear L1 spacers containing 2, 4, or 6 methylene units. Each spacer attaches at the same core position and at a single carbon of the terminal ring. The series holds the remaining substituents constant and varies the number of spacer bonds and the conformations accessible to the terminal ring.

Combination with existing systems

Heteroaryl release from a polymer depot

An aqueous suspension contains a fused bicyclic heteroaryl free base dispersed within poly(lactide-co-glycolide) microspheres. Solvent evaporation from an oil-in-water emulsion hardens the polymer droplets around the compound, and washing removes compound from the particle surfaces. Water enters the microspheres, and the compound diffuses through the hydrated matrix as hydrolysis breaks down the polymer.

Automated or data-driven variant

Automated enumeration of fused heteroaryl analogs

A molecular graph program stores the fused ring connectivity, the atom choices at J1 through J8, and fragments with marked attachment points for L1, L2, and the terminal groups. It substitutes ring atoms and attaches fragments by matching those points to the designated positions on the core. The program checks valence and aromaticity, removes duplicate graphs using canonical molecular identifiers, and records the atom choices and fragment assignments for each retained structure.

Specific version of a part

Pyridine nitrogen at J3

J3 is a pyridine-type nitrogen in the six-membered aromatic ring. Its lone pair lies in the ring plane and serves as a hydrogen-bond acceptor.

Fluorinated carbon at J4

J4 is an aromatic carbon with fluorine as R6. The carbon–fluorine bond projects outward from the ring and places the substituent directly on the aromatic core.

Nitrile substituent at J5

J5 is an aromatic carbon with cyano as R7. The core bonds to the nitrile carbon, and the terminal nitrogen lies along the axis of the carbon–nitrogen triple bond.

Carbon at the J6 junction

J6 is an sp² carbon at one end of the bond shared by the two rings. It bonds to three neighboring ring atoms and contributes a p orbital to the fused aromatic system.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2010/0094017 A1
Published
Apr 15, 2010
Filed
Dec 18, 2009
Class
C07D 213/68
Document BUS 2022/0177473 A1
Published
Jun 9, 2022
Filed
Mar 30, 2020
Class
C07D 471/04
Claim 1
Document A
Document B
1.1J1 is CR3, NR3, O, S, or N
1.2J2 is CR4, NR4, O, S, or N
1.3J3 is CR5 or N
1.4J4 is CR6 or N
1.5J5 is CR7 or N
1.6J6 is C or N
1.7J7 is C or N
1.8J8 is C or N
1.9provided that the bicyclic ring containing J1-J8 is a heteroaryl ring, preferably, the ring of J1, J2, J6, J7, and J8 has 1, 2, or 3 ring nitrogen atoms
Examples of azaaromatic compounds that may be deprotonated by the substituted alkylmetal reagents according to embodiments of the present invention include nitrogen containing six-member ring systems, such as pyridines, quinolines, isoquinolines, acridines, phenanthridines, quinoxalines, oxazines, thiazines, purines, pyrimidines, pyridazines, pyrazines, pteridines, phthalazines, triazines, tetrazines, and the like.
A · US 2010/0094017 A1 · ¶ 14
Generally fused heteroaryl groups also include, but are not limited to, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl; 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolinyl; 2-, 3-, 4-, 5-, 6- or 7-indolyl; 2-, 3-, 4-, 5-, 6- or 7-benzo[b]thienyl; 2-, 4-, 5-, 6- or 7-benzoxazolyl; 2-, 4-, 5-, 6- or 7-benzimidazolyl; 2-, 4-, 5-, 6- or 7-benzothiazolyl; cycloheptadio[d]imidazolyl; 7,8-dihydro-5H-pyrano[4,3-d]pyrimidinyl; 1H-pyrazolo[3,4-d]pyrimidinyl; thieno[3,2-d]pyrimidinyl; 6,7-dihydro-5H-cycl
B · US 2022/0177473 A1 · ¶ 78
1.10L1 is null, an optionally substituted C1-6 alkylene, an optionally substituted C2-6 alkenylene, an optionally substituted C2-6 alkynylene, an optionally substituted 3-8 membered ring, and R1 is an optionally substituted 3-8 membered ring
R2 is selected from C1-6 alkyl, C1-6 heteroalkyl, C6-10 aryl, C5-10 heteroaryl, C4-10 heterocyclyl, C6-10 aryl-C1-6 alkylene, C5-10 heteroaryl-C1-6 alkylene, or C4-10 heterocyclyl-C1-6 alkylene, wherein the alkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted by one or more substituents independently selected from C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, di-C1-6 alkylamino, oxo, halogen, C1-6 haloalkyl, aminoacyl, C1-6 alkylaminoacyl, or di-C1-6 alkylaminoacyl;
B · US 2022/0177473 A1 · ¶ 92
1.11or L1 is null or an optionally substituted 7-12 membered bicyclic ring structure
1.12R1 is hydrogen, deuterium, halogen, CN, OH, NH2, an optionally substituted C1-4 alkyl, an optionally substituted C2-4 alkenyl, an optionally substituted C2-4 alkynyl, an optionally substituted C1-4 heteroalkyl, or an optionally substituted 3-6 membered ring L2 is an optionally substituted C1-4 alkylene or an optionally substituted 3-5 membered carbocyclic or heterocyclic ring, R2 is hydrogen, deuterium, halogen, CN, OH, an optionally substituted C1-4 alkyl, an optionally substituted C2-4 alkenyl, or an optionally substituted C2-4 alkynyl, or an optionally substituted 3-5 membered carbocyclic or heterocyclic ring R3 is hydrogen, deuterium, halogen, CN, G1, OG1, NHG1, NG1G1, C(O)G1, C(O)NHG1, or C(O)NG1G1 R4 is hydrogen, deuterium, halogen, CN, an optionally substituted C1-4 alkyl, an optionally substituted C2-4 alkenyl, an optionally substituted C2-4 alkynyl, an optionally substituted C1-4 heteroalkyl, OG1, NHG1, NG1G1, or an optionally substituted 3-6 membered ring wherein G1 at each occurrence is independently hydrogen, an optionally substituted C1-4 alkyl, an optionally substituted C2-4 alkenyl, an optionally substituted C2-4 alkynyl, an optionally substituted C1-4 heteroalkyl, or an optionally substituted 3-10 membered ring or two G1 together with the nitrogen atom they are both attached to are joined to form an optionally substituted 4-10 membered heterocyclic ring RS is hydrogen, halogen, CN, OH, G2, or L3-G2 wherein L3 is O, NH, CO, C(O)NH, C(O)N(C1-4 alkyl), SO2, SO2NH, SO2N(C1-4 alkyl), an optionally substituted C1-4 alkylene, an optionally substituted C2-4 alkenylene, an optionally substituted C2-4 alkynylene, or an optionally substituted C1-4 heteroalkylene, and G2 is an optionally substituted 3-14 membered ring R6 and R7 are each independently hydrogen, deuterium, halogen, CN, or an optionally substituted C1-4 alkyl.
R3 is selected from hydrogen or C1-6 alkyl; or R2 and R3 together with the nitrogen atom to which they are attached form a heteroaryl or heterocyclyl, preferably a C3-10 heterocyclyl, wherein the heteroaryl or heterocyclyl is optionally substituted by one or more substituents independently selected from C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, di-C1-6 alkylamino, oxo, halogen, C1-6 haloalkyl, aminoacyl, C1-6 alkylaminoacyl, or di-C1-6 alkylaminoacyl; R4 is selected from hydrogen or C1-6 alkyl;
B · US 2022/0177473 A1 · claim 32

An empty cell means only that no passage was reproduced there.

Statements in these documents
Methods for facilitating the metalation of azaaromatic compounds, which are scalable and produce high yields, are therefore desirable.
A · US 2010/0094017 A1 · ¶ 5
The use of substituted alkylmetal reagents to deprotonate azaaromatics produces improved yields and provides scalability to the direct deprotonation process, which have not been realized in other deprotonation processes.
A · US 2010/0094017 A1 · ¶ 8
In other words, there is a need in the art for compounds that exhibit high inhibition of exon 20-inserted EGFR mutants while exhibiting relatively low inhibition of wild-type EGFR, so as to not only exert anticancer efficacy, but also reduce adverse reactions and toxicology associated with the inhibition of wild-type EGFR (e.g., rash and/or diarrhea).
B · US 2022/0177473 A1 · ¶ 4
In order to solve this problem, the inventors have surprisingly found a class of azaaromatic amide compounds, which have a high inhibitory activity against EGFR exon 20 insertion mutations, and some compounds have shown high inhibitory activity against exon 20 point mutations (e.g., S768I, L861Q), HER2 exon 20 insertion mutations and HER4.
B · US 2022/0177473 A1 · ¶ 7
Cite aspatent.fyi, US 2026/0356835 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356835/, SHA-256 54ec0fff2d6f53bffd0dc4a73fb64d1ac2b1faee4bf395bdb5cc90388218d26a
First published
Permanent addresshttps://patent.fyi/US20260356835/
Content fingerprint (SHA-256)54ec0fff2d6f53bffd0dc4a73fb64d1ac2b1faee4bf395bdb5cc90388218d26a
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi